Barits Securities

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company specializing in the development of novel T cell-inducing immunotherapies designed to treat and prevent infectious diseases and cancer. The company's proprietary platforms, ChAdOx and MVA, are engineered to prime and boost the immune system to generate robust and durable T cell responses. Its lead clinical programs include VTP-300, currently in Phase 2 trials for the treatment of chronic hepatitis B, and VTP-200, which targets persistent high-risk human papillomavirus (HPV) infections. Originally established as Vaccitech, a spin-out from the University of Oxford, the company rebranded to Barinthus Biotherapeutics in late 2023 to reflect its strategic focus on therapeutic applications beyond its historical vaccine roots.